MEA Hemophilia Management Market

MEA Hemophilia Management Market Size 

The MEA Hemophilia Management Market is projected to grow from USD 579.26 million in 2025 to USD 589.52 million in 2026 and reach USD 678.35 million by 2034, registering a CAGR of 1.77% from 2026 to 2034.

Hemophilia is a genetic disorder that impairs the body`s ability to control blood clotting.

Hemophilia usually occurs in males; it is estimated that about 1 in 5000 males that are born each year contain hemophilia. Hemophilia is categorized into three levels depending on its severity as severe, moderate, and mild. About 80% of hemophilia patients are considered to suffer from severe type.

The growth of the hemophilia management market in the Middle East and Africa is mainly attributed to the increasing prevalence of hemophilia disorder, favorable health insurance, and healthcare awareness programs. This life-threatening disorder can be treated with plasma-derived clotting factors, recombinant clotting factors, antifibrinolytics, fibrin sealants, and others. In addition, rising healthcare spending and the growing trend to adopt technologically advanced treatment options such as recombinant factor replacement therapies for hemophilia management are driving the market in the MEA region.

The disease is predominantly prevalent in the geriatric population, with a death rate of around 22% if left untreated.

The fertility of hemophiliacs was 2.5 compared to their normal siblings, with 3.5 children per couple. This is anticipated to raise the number of hemophiliacs in the future. For example, according to the World Federation of hemophilia statistics, approximately 4,777 cases of hemophilia have been reported in Egypt, while 520 had von Willebrand disease and 1,200 other bleeding disorders. Among the indications of the illness, the hemophilia A disorder is expected to be more prevalent than hemophilia B in the Middle East and Africa region. It is also reported that 4,250 cases of hemophilia A were recorded and that 38% of them were under four years old. A study published in the journal Medicine in 2017 indicated that hemophilia A is the most common in Saudi Arabia, with the male predisposition.

Recombinant factor replacement therapy market revenues for hemophilia A and B are increasing significantly, which is attributed to increased awareness of the treatment options available for the disease, mainly driven by the recombinant factor replacement therapies in the market. In addition, the promising results shown by factor VIII coagulation factor are in demand with the physicians. Moreover, the market growth can also be attributed to the increase in research and development activities associated with hemophilia and the expansion of pharmaceutical companies on recombinant products, leading to the launch of newer products. All these factors are anticipated to drive the MEA hemophilia management market to greater heights.

However, factors such as higher prices involved with hemophilia treatment options, poor healthcare awareness, strict FDA regulations regarding the drug approval process, lack of R & D in some MEA regions, presence of counterfeit drugs are expected to hamper the growth of the MEA hemophilia management market during the forecast period.

This research report on the MEA Hemophilia Management Market is segmented and sub-segmented into the following categories

MEA Hemophilia Management Market Analysis By Type

• Hemophilia A

• Hemophilia B

MEA Hemophilia Management Market Analysis By Drug

• Octocogalfa

• Nonacogalfa

• Desmopressin

• Other Drugs

MEA Hemophilia Management Market Analysis By Country

• KSA

• UAE

• Israel

• rest of GCC countries

• South Africa

• Ethiopia

• Kenya

• Egypt

• Sudan

• rest of MEA

Geographically, the Middle East is forecasted to occupy the largest regional market share in the MEA hemophilia management market during the forecast period due to more market players and well-developed healthcare facilities for the treatment of hemophilia in the region. In 2023, Saudi Arabia accounted for the largest market share of the Middle East and Africa hemophilia management market. This can be attributed to the increased prevalence of hemophilia, the population's high disposable income, the availability of recombinant coagulation factors, and better reimbursement policies.

Across other MEA countries, the Israel hemophilia management market is expected to experience significant growth during the forecast period due to better medical facilities and sufficient funds for clinical trials for research and development. Egypt is also likely to perform well during the analysis period due to the increasing use of technologically advanced products to treat hemophilia.

In the African region, bleeding disorders have become a significant problem due to limited detection, lack of awareness, and limited access to medical facilities, which are expected to slow the market growth. In addition, healthcare expenses and expenses related to R&D are often expensive and are not affordable in developing economies. Hence the markets in Africa will have a small share in the overall MEA market, although the market is estimated to grow at a steady growth rate.

KEY MARKET PLAYERS

A few notable companies in the Middle East & Africa hemophilia management market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma, and Swedish Orphan Biovitrum AB.